Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection (Q61690576)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 September 2009

Language	Label	Description	Also known as
English	Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection	scientific article published on 10 September 2009

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

molecular medicine

0 references

antibiotic resistance

1 reference

based on heuristic

inferred from title

Leishmania infantum

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Pedro J Alcolea

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

author name string

A Alonso

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

A Peris

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J M Marcen

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

M A Abengozar

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

J A Castillo

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

V Larraga

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

language of work or name

0 references

publication date

10 September 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

48

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

6695-6703

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Decreased sensitivity to meglumine antimoniate (Glucantime) ofLeishmania infantumisolated from dogs after several courses of drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Drug resistance in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Leishmaniasis: new approaches to disease control

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T-cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Analysis of the cellular parameters of the immune responses contributing to resistance and susceptibility of mice to infection with the intracellular parasite, Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Immunology of canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Cutaneous leishmaniasis in naturally infected dogs is associated with a T helper-2-biased immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Tissue cytokine responses in canine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Expression cloning of a protective Leishmania antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

DNA vaccines induce partial protection against Leishmania mexicana

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Ensuring safety of DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

A novel antibiotic free plasmid selection system: advances in safe and efficient DNA therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Advantages of real-time PCR assay for diagnosis and monitoring of canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

A heterologous prime/boost immunisation strategy protects against virulent E. ruminantium Welgevonden needle challenge but not against tick challenge.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Associations among immunological, parasitological and clinical parameters in canine visceral leishmaniasis: Emaciation, spleen parasitism, specific antibodies and leishmanin skin test reaction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Humoral and cell-mediated immunity in natural and experimental canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Isotype patterns of immunoglobulins: hallmarks for clinical status and tissue parasite density in Brazilian dogs naturally infected by Leishmania (Leishmania) chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

The separation and identification by monoclonal antibodies of dog IgG fractions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Immunoglobulin G subclass distribution in canine leishmaniosis: a review and analysis of pitfalls in interpretation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Analysis of the humoral immune response against total and recombinant antigens of Leishmania infantum: correlation with disease progression in canine experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Anti-Leishmania humoral and cellular immune responses in naturally infected symptomatic and asymptomatic dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Cell mediated immunity and specific IgG1 and IgG2 antibody response in natural and experimental canine leishmaniosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Perforin and gamma interferon are critical CD8+ T-cell-mediated responses in vaccine-induced immunity against Leishmania amazonensis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Cross-talk between CD8(+) and CD4(+) T cells in experimental cutaneous leishmaniasis: CD8(+) T cells are required for optimal IFN-gamma production by CD4(+) T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Leishmania: naive human T cells sensitized with promastigote antigen and IL-12 develop into potent Th1 and CD8(+) cytotoxic effectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

The interaction between CD8+ cytotoxic T cells and Leishmania-infected macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Nitric oxide production by macrophages of dogs vaccinated with killed Leishmania infantum promastigotes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.08.091

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.08.091

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19747996%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61690576&oldid=1754776571"